BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

305 related articles for article (PubMed ID: 23454164)

  • 1. Efficacy of RTS,S malaria vaccines: individual-participant pooled analysis of phase 2 data.
    Bejon P; White MT; Olotu A; Bojang K; Lusingu JP; Salim N; Otsyula NN; Agnandji ST; Asante KP; Owusu-Agyei S; Abdulla S; Ghani AC
    Lancet Infect Dis; 2013 Apr; 13(4):319-27. PubMed ID: 23454164
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Environmental modifiers of RTS,S/AS01 malaria vaccine efficacy in Lilongwe, Malawi.
    Bell GJ; Loop MS; Mvalo T; Juliano JJ; Mofolo I; Kamthunzi P; Tegha G; Lievens M; Bailey J; Emch M; Hoffman I
    BMC Public Health; 2020 Jun; 20(1):910. PubMed ID: 32532234
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Immunogenicity of the RTS,S/AS01 malaria vaccine and implications for duration of vaccine efficacy: secondary analysis of data from a phase 3 randomised controlled trial.
    White MT; Verity R; Griffin JT; Asante KP; Owusu-Agyei S; Greenwood B; Drakeley C; Gesase S; Lusingu J; Ansong D; Adjei S; Agbenyega T; Ogutu B; Otieno L; Otieno W; Agnandji ST; Lell B; Kremsner P; Hoffman I; Martinson F; Kamthunzu P; Tinto H; Valea I; Sorgho H; Oneko M; Otieno K; Hamel MJ; Salim N; Mtoro A; Abdulla S; Aide P; Sacarlal J; Aponte JJ; Njuguna P; Marsh K; Bejon P; Riley EM; Ghani AC
    Lancet Infect Dis; 2015 Dec; 15(12):1450-8. PubMed ID: 26342424
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy and safety of the RTS,S/AS01 malaria vaccine during 18 months after vaccination: a phase 3 randomized, controlled trial in children and young infants at 11 African sites.
    RTS,S Clinical Trials Partnership
    PLoS Med; 2014 Jul; 11(7):e1001685. PubMed ID: 25072396
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Public health impact and cost-effectiveness of the RTS,S/AS01 malaria vaccine: a systematic comparison of predictions from four mathematical models.
    Penny MA; Verity R; Bever CA; Sauboin C; Galactionova K; Flasche S; White MT; Wenger EA; Van de Velde N; Pemberton-Ross P; Griffin JT; Smith TA; Eckhoff PA; Muhib F; Jit M; Ghani AC
    Lancet; 2016 Jan; 387(10016):367-375. PubMed ID: 26549466
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy of RTS,S/AS02 malaria vaccine against Plasmodium falciparum infection in semi-immune adult men in The Gambia: a randomised trial.
    Bojang KA; Milligan PJ; Pinder M; Vigneron L; Alloueche A; Kester KE; Ballou WR; Conway DJ; Reece WH; Gothard P; Yamuah L; Delchambre M; Voss G; Greenwood BM; Hill A; McAdam KP; Tornieporth N; Cohen JD; Doherty T;
    Lancet; 2001 Dec; 358(9297):1927-34. PubMed ID: 11747915
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Safety and efficacy of the RTS,S/AS01E candidate malaria vaccine given with expanded-programme-on-immunisation vaccines: 19 month follow-up of a randomised, open-label, phase 2 trial.
    Asante KP; Abdulla S; Agnandji S; Lyimo J; Vekemans J; Soulanoudjingar S; Owusu R; Shomari M; Leach A; Jongert E; Salim N; Fernandes JF; Dosoo D; Chikawe M; Issifou S; Osei-Kwakye K; Lievens M; Paricek M; Möller T; Apanga S; Mwangoka G; Dubois MC; Madi T; Kwara E; Minja R; Hounkpatin AB; Boahen O; Kayan K; Adjei G; Chandramohan D; Carter T; Vansadia P; Sillman M; Savarese B; Loucq C; Lapierre D; Greenwood B; Cohen J; Kremsner P; Owusu-Agyei S; Tanner M; Lell B
    Lancet Infect Dis; 2011 Oct; 11(10):741-9. PubMed ID: 21782519
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical development of RTS,S/AS malaria vaccine: a systematic review of clinical Phase I-III trials.
    Agnandji ST; Fernandes JF; Bache EB; Ramharter M
    Future Microbiol; 2015; 10(10):1553-78. PubMed ID: 26437872
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A phase 3 trial of RTS,S/AS01 malaria vaccine in African infants.
    ; Agnandji ST; Lell B; Fernandes JF; Abossolo BP; Methogo BG; Kabwende AL; Adegnika AA; Mordmüller B; Issifou S; Kremsner PG; Sacarlal J; Aide P; Lanaspa M; Aponte JJ; Machevo S; Acacio S; Bulo H; Sigauque B; Macete E; Alonso P; Abdulla S; Salim N; Minja R; Mpina M; Ahmed S; Ali AM; Mtoro AT; Hamad AS; Mutani P; Tanner M; Tinto H; D'Alessandro U; Sorgho H; Valea I; Bihoun B; Guiraud I; Kaboré B; Sombié O; Guiguemdé RT; Ouédraogo JB; Hamel MJ; Kariuki S; Oneko M; Odero C; Otieno K; Awino N; McMorrow M; Muturi-Kioi V; Laserson KF; Slutsker L; Otieno W; Otieno L; Otsyula N; Gondi S; Otieno A; Owira V; Oguk E; Odongo G; Woods JB; Ogutu B; Njuguna P; Chilengi R; Akoo P; Kerubo C; Maingi C; Lang T; Olotu A; Bejon P; Marsh K; Mwambingu G; Owusu-Agyei S; Asante KP; Osei-Kwakye K; Boahen O; Dosoo D; Asante I; Adjei G; Kwara E; Chandramohan D; Greenwood B; Lusingu J; Gesase S; Malabeja A; Abdul O; Mahende C; Liheluka E; Malle L; Lemnge M; Theander TG; Drakeley C; Ansong D; Agbenyega T; Adjei S; Boateng HO; Rettig T; Bawa J; Sylverken J; Sambian D; Sarfo A; Agyekum A; Martinson F; Hoffman I; Mvalo T; Kamthunzi P; Nkomo R; Tembo T; Tegha G; Tsidya M; Kilembe J; Chawinga C; Ballou WR; Cohen J; Guerra Y; Jongert E; Lapierre D; Leach A; Lievens M; Ofori-Anyinam O; Olivier A; Vekemans J; Carter T; Kaslow D; Leboulleux D; Loucq C; Radford A; Savarese B; Schellenberg D; Sillman M; Vansadia P
    N Engl J Med; 2012 Dec; 367(24):2284-95. PubMed ID: 23136909
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Randomized controlled trial of RTS,S/AS02D and RTS,S/AS01E malaria candidate vaccines given according to different schedules in Ghanaian children.
    Owusu-Agyei S; Ansong D; Asante K; Kwarteng Owusu S; Owusu R; Wireko Brobby NA; Dosoo D; Osei Akoto A; Osei-Kwakye K; Adjei EA; Boahen KO; Sylverken J; Adjei G; Sambian D; Apanga S; Kayan K; Vekemans J; Ofori-Anyinam O; Leach A; Lievens M; Demoitie MA; Dubois MC; Cohen J; Ballou WR; Savarese B; Chandramohan D; Gyapong JO; Milligan P; Antwi S; Agbenyega T; Greenwood B; Evans J
    PLoS One; 2009 Oct; 4(10):e7302. PubMed ID: 19806184
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Duration of vaccine efficacy against malaria: 5th year of follow-up in children vaccinated with RTS,S/AS02 in Mozambique.
    Campo JJ; Sacarlal J; Aponte JJ; Aide P; Nhabomba AJ; Dobaño C; Alonso PL
    Vaccine; 2014 Apr; 32(19):2209-16. PubMed ID: 24631081
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Seven-Year Efficacy of RTS,S/AS01 Malaria Vaccine among Young African Children.
    Olotu A; Fegan G; Wambua J; Nyangweso G; Leach A; Lievens M; Kaslow DC; Njuguna P; Marsh K; Bejon P
    N Engl J Med; 2016 Jun; 374(26):2519-29. PubMed ID: 27355532
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Design of a phase III multicenter trial to evaluate the efficacy of the RTS,S/AS01 malaria vaccine in children across diverse transmission settings in Africa.
    Leach A; Vekemans J; Lievens M; Ofori-Anyinam O; Cahill C; Owusu-Agyei S; Abdulla S; Macete E; Njuguna P; Savarese B; Loucq C; Ballou WR;
    Malar J; 2011 Aug; 10():224. PubMed ID: 21816029
    [TBL] [Abstract][Full Text] [Related]  

  • 14. First results of phase 3 trial of RTS,S/AS01 malaria vaccine in African children.
    ; Agnandji ST; Lell B; Soulanoudjingar SS; Fernandes JF; Abossolo BP; Conzelmann C; Methogo BG; Doucka Y; Flamen A; Mordmüller B; Issifou S; Kremsner PG; Sacarlal J; Aide P; Lanaspa M; Aponte JJ; Nhamuave A; Quelhas D; Bassat Q; Mandjate S; Macete E; Alonso P; Abdulla S; Salim N; Juma O; Shomari M; Shubis K; Machera F; Hamad AS; Minja R; Mtoro A; Sykes A; Ahmed S; Urassa AM; Ali AM; Mwangoka G; Tanner M; Tinto H; D'Alessandro U; Sorgho H; Valea I; Tahita MC; Kaboré W; Ouédraogo S; Sandrine Y; Guiguemdé RT; Ouédraogo JB; Hamel MJ; Kariuki S; Odero C; Oneko M; Otieno K; Awino N; Omoto J; Williamson J; Muturi-Kioi V; Laserson KF; Slutsker L; Otieno W; Otieno L; Nekoye O; Gondi S; Otieno A; Ogutu B; Wasuna R; Owira V; Jones D; Onyango AA; Njuguna P; Chilengi R; Akoo P; Kerubo C; Gitaka J; Maingi C; Lang T; Olotu A; Tsofa B; Bejon P; Peshu N; Marsh K; Owusu-Agyei S; Asante KP; Osei-Kwakye K; Boahen O; Ayamba S; Kayan K; Owusu-Ofori R; Dosoo D; Asante I; Adjei G; Adjei G; Chandramohan D; Greenwood B; Lusingu J; Gesase S; Malabeja A; Abdul O; Kilavo H; Mahende C; Liheluka E; Lemnge M; Theander T; Drakeley C; Ansong D; Agbenyega T; Adjei S; Boateng HO; Rettig T; Bawa J; Sylverken J; Sambian D; Agyekum A; Owusu L; Martinson F; Hoffman I; Mvalo T; Kamthunzi P; Nkomo R; Msika A; Jumbe A; Chome N; Nyakuipa D; Chintedza J; Ballou WR; Bruls M; Cohen J; Guerra Y; Jongert E; Lapierre D; Leach A; Lievens M; Ofori-Anyinam O; Vekemans J; Carter T; Leboulleux D; Loucq C; Radford A; Savarese B; Schellenberg D; Sillman M; Vansadia P
    N Engl J Med; 2011 Nov; 365(20):1863-75. PubMed ID: 22007715
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Long-term incidence of severe malaria following RTS,S/AS01 vaccination in children and infants in Africa: an open-label 3-year extension study of a phase 3 randomised controlled trial.
    Tinto H; Otieno W; Gesase S; Sorgho H; Otieno L; Liheluka E; Valéa I; Sing'oei V; Malabeja A; Valia D; Wangwe A; Gvozdenovic E; Guerra Mendoza Y; Jongert E; Lievens M; Roman F; Schuerman L; Lusingu J
    Lancet Infect Dis; 2019 Aug; 19(8):821-832. PubMed ID: 31300331
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Safety, immunogenicity and duration of protection of the RTS,S/AS02(D) malaria vaccine: one year follow-up of a randomized controlled phase I/IIb trial.
    Aide P; Aponte JJ; Renom M; Nhampossa T; Sacarlal J; Mandomando I; Bassat Q; Manaca MN; Leach A; Lievens M; Vekemans J; Dubois MC; Loucq C; Ballou WR; Cohen J; Alonso PL
    PLoS One; 2010 Nov; 5(11):e13838. PubMed ID: 21079803
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A randomized trial assessing the safety and immunogenicity of AS01 and AS02 adjuvanted RTS,S malaria vaccine candidates in children in Gabon.
    Lell B; Agnandji S; von Glasenapp I; Haertle S; Oyakhiromen S; Issifou S; Vekemans J; Leach A; Lievens M; Dubois MC; Demoitie MA; Carter T; Villafana T; Ballou WR; Cohen J; Kremsner PG
    PLoS One; 2009 Oct; 4(10):e7611. PubMed ID: 19859560
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The public health impact and cost-effectiveness of the R21/Matrix-M malaria vaccine: a mathematical modelling study.
    Schmit N; Topazian HM; Natama HM; Bellamy D; Traoré O; Somé MA; Rouamba T; Tahita MC; Bonko MDA; Sourabié A; Sorgho H; Stockdale L; Provstgaard-Morys S; Aboagye J; Woods D; Rapi K; Datoo MS; Lopez FR; Charles GD; McCain K; Ouedraogo JB; Hamaluba M; Olotu A; Dicko A; Tinto H; Hill AVS; Ewer KJ; Ghani AC; Winskill P
    Lancet Infect Dis; 2024 May; 24(5):465-475. PubMed ID: 38342107
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Seasonal use case for the RTS,S/AS01 malaria vaccine: a mathematical modelling study.
    Thompson HA; Hogan AB; Walker PGT; Winskill P; Zongo I; Sagara I; Tinto H; Ouedraogo JB; Dicko A; Chandramohan D; Greenwood B; Cairns M; Ghani AC
    Lancet Glob Health; 2022 Dec; 10(12):e1782-e1792. PubMed ID: 36400084
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Safety of the malaria vaccine candidate, RTS,S/AS01E in 5 to 17 month old Kenyan and Tanzanian Children.
    Lusingu J; Olotu A; Leach A; Lievens M; Vekemans J; Olivier A; Benns S; Olomi R; Msham S; Lang T; Gould J; Hallez K; Guerra Y; Njuguna P; Awuondo KO; Malabeja A; Abdul O; Gesase S; Dekker D; Malle L; Ismael S; Mturi N; Drakeley CJ; Savarese B; Villafana T; Ballou WR; Cohen J; Riley EM; Lemnge MM; Marsh K; Bejon P; von Seidlein L
    PLoS One; 2010 Nov; 5(11):e14090. PubMed ID: 21124768
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.